PURIFICATION OF HTLV-I RECOMBINANT ENVELOPE ANTIGEN

Information

  • Research Project
  • 3488800
  • ApplicationId
    3488800
  • Core Project Number
    R43AI026417
  • Full Project Number
    1R43AI026417-01
  • Serial Number
    26417
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1988 - 36 years ago
  • Project End Date
    9/30/1988 - 35 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1988 - 36 years ago
  • Budget End Date
    9/30/1988 - 35 years ago
  • Fiscal Year
    1988
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/23/1988 - 36 years ago
Organizations

PURIFICATION OF HTLV-I RECOMBINANT ENVELOPE ANTIGEN

The long term objective of the research initiated by this proposal is to develop an improved diagnostic assay for detection of antibodies to HTLV-I in human sera using recombinant DNA derived antigens. HTLV-I is a human retrovirus that has been shown to cause a form of adult T-cell leukemia, and has been linked by some researchers to a number of neurotropic diseases. Infection is spread primarily through intimate personal contact or direct blood contact. An assay to detect evidence of infection by HTLV-I must have excellent sensitivity and specificity characteristics, and be suitable for large scale automated analysis. Key components in the development of such an assay are procedures for large scale fermentation of the E. coli cultures producing the antigen, and procedures for antigen purification. In general, recombinant DNA derived proteins expressed in E. coli have proven to be particularly difficult to purify because of their poor solubility and tendency to form aggregates in the absence of strong denaturants. The research plan in this proposal will make use of conventional protein purification methodology, novel protein modification methods that allow solubility in non- denaturing buffers, and high performance chromatography to purify HTLV-I recombinant envelope antigens.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    ANTIGENICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LEXINGTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02421
  • Organization District
    UNITED STATES